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ABSTRACT
Objective: To investigate the frequency of thyroid disorders (TD) in patients with chronic hepa-
titis C before and during interferon-alpha (IFN-α) and ribavirin (RIB) treatment. Study design: 
Prospective study. Patients and Methods: We prospectively studied 65 anti-HCV and viral RNA 
positive patients. Free thyroxine, thyroid-stimulating hormone, and thyroid peroxidase antibodies 
(TPO-Ab) were systematically tested at entry (m0), week 12 (m3) and week 24 (m6) of treatment. 
Results: Mean age of the 65 patients (38 females and 27 males) was 49.61 ± 11.83 years. Seven 
(10.76%) patients presented baseline thyroid disorders (m0), three had thyroid dysfunction, and 
four were TPO-Ab positive. Thyroid disorders occurred in the first 12 weeks of treatment in 11 
(16.92%) patients, four with thyroid dysfunction, and seven with TPO-Ab positive (m3). A total 
of 18 patients (27.69%) developed TD after 24 weeks of treatment, 7 with thyroid dysfunction, and 
11 with TPO-Ab positive (m6). The relative risk of developing hypothyroidism found in this study 
was 1.3 (95% CI: 1.1 to 1.6), hyperthyroidism 1.2 (95% CI: 1.1 to 1.4), and TPO-Ab positivity 7.6 
(95% CI: 3.9 to 14.5). The study showed a significant association between female sex and thyroid 
disease (p = 0.009). Conclusion: Thyroid dysfunction and autoimmune TD were observed during 
IFN-α and RIB therapy.
Keywords: hepatitis C; interferon-alpha; ribavirin; thyroid diseases; autoimmunity.
INTRODUCTION
Thyroid dysfunction represents one of the com-
monest endocrine manifestations of chronic 
hepatitis C infection (HCV), exacerbated by in-
terferon-based treatment.1 Changes in thyroid 
function are common side-effects occurring 
during antiviral therapy with interferon-alpha 
(IFN-α). In this way, the spectrum of thyroid 
diseases range from the production of isolat- 
ed anti-thyroid antibodies to dysfunctions such 
as hypothyroidism, Graves’ disease (GD), and 
destructive thyroiditis.2
IFN-α therapy for HCV may induce thy-
roid changes or dysfunction in 2.5% to 20% 
of treated patients. Up to 40% become thyroid 
antibody positive, and these side-effects can 
interfere with effective management of HCV.3,4
Almost all side-effects of IFN-α treatment 
are due to its effects on the immune system, and 
data suggest that in addition to its immu-
nomodulatory mechanism, IFN-α also precipi-
tates thyroiditis by direct thyrotoxicity.4
Ribavirin (RIB) is a nucleoside analogue 
with broad spectrum activity against several 
RNA and DNA viruses, and it could possi-
bly stimulate the immune system alone or 
synergistically with IFN-α to cause thyroid 
disease via an autoimmune mechanism.5 
RIB can also enhance non-virus-induced 
immune response, suggesting that this drug 
could trigger autoimmune phenomena in 
predisposed patients.6 Thyroid dysfunc-
tion is more prevalent in patients treated 
with IFN-α and RIB combination therapy 
(12.1%) than in patients treated with IFN-α 
alone (6.6%).7
Additionally, hepatitis C virus is both a 
hepatotropic as well as a lymphotropic vi-
rus and can modulate T cell and B cell an-
tibody responses, affecting most commonly 
the thyroid.8,9 However, morphological 
evidence of hepatitis C virus replication in 
thyroid cells in immune competent patients 
has not been demonstrated.10 The objective 
of this study was to assess the frequency of 
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thyroid disorders in patients with HCV before and dur-
ing long term IFN-α and RIB therapy, and to assess the 
relative risk of dysthyroidism in this population.
MATERIALS AND METHODS
Study design
This prospective study was conducted at the Gastro-Hepa-
tology Unit, Universidade Federal da Bahia, Salvador, Bra-
zil, and all patients gave their informed consent to partici-
pate. The study was approved by the ethical committee of 
Universidade Estadual de Santa Cruz, Bahia, Brazil, in ac-
cordance to the Declaration of Helsinki.
Thyroid disease was investigated in all patients by tests 
that included thyroid stimulating hormone (TSH), free 
thyroxine (FT4), and antithyroid peroxidase antibody 
(TPO-Ab) titers, before initiating treatment (m0), at week 
12 (m3) and at the end week 24 of treatment (m6). Other 
autoimmune diseases were not investigated in this study. 
Thyrotropin receptor antibodies (TRAb) are useful in the 
diagnosis of GD disease. Measurements of TRAb were only 
performed in patients who had clinical hyperthyroidism to 
assess whether the GD was active.
Study patients
Our study included 65 patients admitted for HCV infection 
to the Gastro-Hepatology Unit, Universidade Federal da Ba-
hia, Salvador, Brazil. The eligibility criteria were: I) serum 
anti-HCV antibody and HCV RNA positivity; II) chronic 
inflammation confirmed by histological analysis of the liver; 
III) available genotyping; and IV) treatment-naïve patients.
Virological assays
Detection of antibodies to HCV (anti-HCV) was meas-
ured by enzyme-linked immunosorbent assay, using 
structural and non-structural HCV antigens (AXSYM Sys-
tem; Abbott Laboratories, Chicago, IL, USA). HCV-RNA 
were quantified by polymerase chain reaction (RT-PCR) 
using primers derived from the highly conserved region 
5’UTR (untranslated region) of the viral genome (Ampli-
cor® HCV Detection KIT V2.0; Roche Molecular Systems 
Inc., Somerville, NJ, USA). HCV genotyping was per-
formed by INNOLIPA (Innogenetics, NV, Gent, Belgium). 
Genotypes were classified according to Simmonds et al.11
Liver histopathology
All subjects positive for HCV-RNA underwent percuta-
neous liver biopsy, obtained blindly (Hepafix 1.4 mm, B. 
Braun, Germany), and histological parameters were classi-
fied according to the score system of inflammation activity 
and fibrosis. Liver biopsy specimens were obtained before 
initiation of therapy and were evaluated by a single liver 
pathologist with expertise and blinded to the study design.
Histological abnormalities of liver biopsies were scored 
according to the METAVIR system. Liver fibrosis was staged 
on a scale of 0 - 4, here 0 = no fibrosis, 1 = portal fibrosis with-
out septa, 2 = few septa, 3 = numerous septa without cirrhosis, 
and 4 = cirrhosis. Necroinflammatory activity was graded on a 
scale of A0-A3, where A0 = no histological activity, A1 = mild 
activity, A2 = moderate activity, and A3 = severe activity.12,13
Evaluation of thyroid function and antibody thyroid 
screening
TSH (ultrasensitive third-generation method with a refer-
ence normal range of 0.35-5.50 mcIU/L), and FT4 (reference 
normal range of 0.58-1.40 ng/dL) were assayed using com-
mercially available kits by immunometric assays.
TPO-Ab was detected by solid phase 2-site sequen-
tial chemiluminescent immunometric assay (normal: 
< 40.0 IU/mL). Patients were classified as positive 
(TPO-Ab > 40.0 IU/mL) or negative (TPO-Ab > 40.0 
IU/mL) for thyroid autoimmunity.
Study outcomes
The primary outcome of this study was the development of 
thyroid dysfunction during IFN-α and RIB therapy. Second-
ary outcomes included frequency of TPO-Ab at the end week 
24 of HCV therapy. The association between viral load and 
sustained virological response (SVR) with the development 
of thyroid disorders was not assessed in this study protocol.
Statistical analysis
Data are expressed as mean ± SD for those variables that were 
normally distributed. Statistical analysis was performed using 
chi-square or Fischer’s exact test. Relative risk was calculated 
by using the one-tailed exact method for the combination of 
2 × 2 tables, computing 95% confidence intervals (CI).
Statistical analysis was performed using SPSS® version 
16.0 for Windows (SPSS Inc, Chicago, Ill), and a p-value 
< 0.05 was considered statistically significant.
RESULTS
Mean age of the 65 patients (38 females and 27 males) was 
49.61 ± 11.83 years (range: 22-66 years). Other major charac-
teristics of the 65 studied patients before treatment are shown 
in Table 1.
Table 1. Characteristics of the study patients
Characteristics Total
Genotype (1/2/3) 46/1/18
Stage of fibrosis (1/2/3/4) 7/37/16/5
Necroinflammatory activity (0/1/2/3) 13/20/30/2
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Thyroid function and TPO-Ab before treatment 
Before treatment (m0), thyroid function tests and TPO-Ab 
titers were evaluated in all patients. Seven (10.76%) patients 
presented baseline thyroid disorders, one individual had overt 
hypothyroidism, one subclinical hypothyroidism, one subclini-
cal hyperthyroidism, and four were positive for TPO-Ab.
Titers of positive TPO-Ab cases were similar for females 
and males (about 3.07%). The positivity of TPO-Ab be-
fore treatment was more commonly found in patients with 
thyroid dysfunction than those without thyroid disorders 
(p = 0.04). No significant association was found among sex, 
age, HCV genotypes, or METAVIR with thyroid disorders at 
baseline. Patients who had thyroid dysfunction were treated 
before the start of therapy with IFN-α and RIB.
Thyroid function and TPO-Ab at week 12 of treatment 
After 12 weeks of treatment (m3), two patients (3.07%) devel-
oped subclinical hypothyroidism de novo, one patient (1.54%) 
developed clinically overt hyperthyroidism de novo, and three 
patients (4.62%) presented positive TPO-Ab titers de novo. 
One case of subclinical hypothyroidism de novo occurred 
during treatment was associated with TPO-Ab positivity. 
Statistical analysis showed significant correlation between the 
development de novo thyroid dysfunction during IFN-α and 
RIB treatment and TPO-Ab positivity at week 12 of treatment 
(p = 0.001). Out of 11 cases with thyroid disorders at the 
end of the 12th week of treatment (16.92%), four cases had thy-
roid dysfunction and seven had positive TPO-Ab, including 
baseline and de novo cases. Patients who had thyroid dysfunc-
tion were treated upon diagnosis.
Thyroid function and TPO-Ab at the end of week 24 
of treatment 
At the end of 24 weeks of treatment (m6), three (4.62%) 
patients developed thyroid dysfunction (two subclinical 
hypothyroidism, and one subclinical hyperthyroidism 
de novo), and four patients (6.15%) presented positive 
TPO-Ab titers de novo. No case of thyroid dysfunction 
de novo occurred during treatment associated with TPO-
Ab positivity assessed at week 24 of treatment. There-
fore, 18 cases of thyroid disorders occurred at the end 
of 24 weeks of treatment (27.69%), being seven cases of 
thyroid dysfunction, four individuals had subclinical 
hypothyroidism, and three subclinical hyperthyroidism 
(p = 0.006). Additionally, 11 cases of positive TPO-Ab 
were diagnosed including baseline, 12 weeks of treat-
ment, and de novo cases (Table 2).
The relative risk (RR) of developing thyroid autoim-
munity was significantly higher among those who de-
veloped thyroid dysfunction. It was found that the RR of 
developing hypothyroidism in this study was 1.3 (95% CI 
1.1 to 1.6; p = 0.02), of hyperthyroidism was 1.2 (95% 
CI 1.1 to 1.4; p = 0.02), and of TPO-Ab positivity was 7.6 
(95% CI 3.9 to 14.5; p = 0.001). The RR of developing thy-
roid autoimmunity in HCV carriers treated with IFN-α 
and RIB was 5.8 times higher than the risk for developing 
thyroid disorders.
The thyroid disorders occurred more often in female pa-
tients aged over 40 years old, with a significant association 
(p = 0.009) when analyzed after 12 weeks of therapy. The as-
sociation between viral load, and SVR with the development 
of thyroid disorders at the end of the m6 was not assessed.
DISCUSSION
This study reports the frequency of thyroid disorders 
(thyroid dysfunction and thyroid autoimmunity) before 
and during antiviral combination therapy with IFN-α and 
RIB for HCV. The frequency of thyroid disease at the end of 
24 weeks of antiviral therapy with IFN-α and RIB therapy 
for HCV were 27.69% in our study (10.77% and 16.92% for 
thyroid dysfunction and TPO-Ab positivity respectively). 
Table 2. Thyroid function test before, at week 12, and at week 24 of treatment
 Thyroid function  Thyroid function Thyroid function 
 before treatment 12 weeks of treatment 24 weeks of treatment
 Normal Anormal Positive Negative Normal Anormal Positive Negative Normal Anormal Positive Negative 
 (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%) (%)
FT4 64 1 (1.54)   64 1 (1.54)   64 1 (1.54) 
 (98.46)    (98.46)    (98.46)
TSH 62 3 (4.62)   60 5   60 7 
 (95.38)    (92.30) (7.70)**   (89.23) (10.77)****
TIPO-   4 61   7 58   11 54 
Ab   (6.15)* (93.85)   (10.77)*** (89.23)   (16.92)***** (83.08)
*p = 0.04; **p = 0.0001; ***p = 0.0001; ****p = 0.0006; *****p = 0.08.
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Our series demonstrates a wide spectrum of thyroid 
diseases, ranging from overt hypothyroidism and hyper-
thyroidism, and thyroiditis until subclinical hypothyroidism 
or hyperthyroidism. These findings are in agreement with 
previous studies reporting thyroid dysfunction between 
2.5% and 20%, with a mean incidence of 12.1%, and up to 
40% of patients becoming thyroid antibody positive un-
der therapy with IFN-α and RIB.3,4
Several extrahepatic diseases have been associated 
with HCV, but thyroid disorders are the most common 
endocrinopathy, exacerbated by IFN-α and RIB treat-
ment.14 IFN-induced thyroid disease exhibits features from 
both drug-induced thyroiditis and autoimmune thyroid 
disease. However, the mechanisms of induced thyroid dis-
ease are complex and not completely understood. The clear 
association between autoimmune thyroid disease and 
IFN-α use suggests that high endogenous IFN-α levels 
may also be associated with naturally autoimmune thy-
roid disease.15 RIB is a nucleoside analogue with broad 
spectrum activity against several RNA and DNA viruses 
with immunomodulatory effects. It is possible that RIB 
may stimulate the immune system alone or synergisti-
cally with IFN-α to cause thyroid disease via an autoim-
mune mechanism.16
IFN-induced autoimmune thyroid disease is associ-
ated with elevated auto-antibodies and may manifest with 
or without clinical disease.17 The presence of TPO-AB 
prior to IFN-α therapy carries a relative risk of 3.9 (95% 
CI 1.9-8.1) for thyroid disease.15 Ours results showed an 
increased frequency of TPO-Ab positivity after initiation 
of therapy with IFN-α and RIB. The relative risk of devel-
oping thyroid autoimmunity among HCV carriers treated 
with IFN-α and RIB was 5.8 times higher than the risk for 
developing hypothyroidism or hyperthyroidism.
Recent biochemical advances have led to the develop-
ment of highly sensitive assays of serum TSH and FT4 
for the biochemical assessment of thyroid function. TSH 
is the most sensitive marker of thyroid function, its deter-
mination with these new tools makes it possible to detect 
both subclinical hypo- and hyperthyroidism (elevated or 
decreased TSH, with normal FT4, respectively). The rate 
of subclinical forms of thyroid dysfunction is significant-
ly higher in patients treated with IFN-α for HCV.18 This 
study showed a higher frequency of subclinical thyroid 
dysfunction. These findings have been found by other 
investigators and suggest that combination therapy for 
HCV can be continued, even in those who develop overt 
thyroid disease.19
IFN-α can trigger the development of hyperthyroidism 
in predisposed individuals.20 In previous studies, the in-
cidence of hyperthyroidism during IFN- α -based therapy 
was 1-2%.21 In this study our data is in accordance with 
the literature, where one case developed hyperthyroidism 
following IFN-α therapy and did not recover after the end 
of the antiviral therapy.
The strongest risk factors that were associated with an in-
creased risk of development of thyroid disease during IFN-α 
therapy were female gender and the presence of TPO-Ab 
before the initiation of therapy. In this way, the risk among 
females increases directly with increasing age.15,22 Our study 
showed a significant association between female gender 
with age over 40 years old and thyroid disease.
Rodríguez-Torres et al.23 demonstrated that patients with 
HCV and severe fibrosis have higher probability of prior 
history of thyroid disorders and are more prone to develop 
thyroid disorders events during treatment with IFN-α than 
patients with mild fibrosis. Our study showed no significant 
differences between thyroid dysfunction patients and liver 
inflammation or fibrosis grade, but it should be pointed out 
that 89.2% of patients presented a stage of fibrosis equal to 
or above F2.
Significant association between thyroid disease and 
SVR was described by Tran et al.14, which was not support-
ed by meta-analysis. The association between viral load, 
and SVR with the development of thyroid disorders was 
not part of this study protocol, considering that our prima-
ry objective was the development of thyroid dysfunction 
during IFN-α and RIB therapy, and the secondary objec-
tive was frequency of TPO-Ab at the end of 24 weeks of 
HCV therapy. Despite the lack of supportive evidence from 
meta-analysis, it is important that future studies be done to 
confirm or reject these results.
CONCLUSION
In conclusion, this study shows important clarification of 
the association between HCV treatment and thyroid dis-
orders. Accordingly, some guidelines may be suggested as 
follows: patients who are treated with IFN-α and RIB thera-
py should be informed about the risks of developing thyroid 
dysfunction, and therefore screening of thyroid function 
and the panel of antibodies should be evaluated before and 
during treatment of HCV.
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